We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada.
- Authors
Goy, Jennifer; Gillan, Tanya L.; Bruyere, Helene; Huang, Steven J.T.; Hrynchak, Monica; Karsan, Aly; Ramadan, Khaled; Connors, Joseph; Toze, Cynthia L.; Gerrie, Alina S.
- Abstract
<bold>Background: </bold>Chronic lymphocytic leukemia (CLL) patients with 11q22.3 deletion (11q-) have an aggressive clinical course, and thus selection of first-line therapy in this group is important. This study aimed to improve our understanding of real-world practice patterns and outcomes of CLL patients with 11q- in a population-based setting.<bold>Patients and Methods: </bold>The British Columbia CLL Database was used to identify patients with 11q-. Overall survival (OS) and treatment-free survival (TFS) were assessed after adjustment for prognostic factors.<bold>Results: </bold>Of 1044 patients in the database, 125 had 11q- (12%). Sixty-nine patients had 11q- identified before therapy initiation and had a median OS and TFS of 14.7 (95% confidence interval [CI], 11.3-18.1) and 2.5 (95% CI, 1.5-3.6) years. Patient with copresence of 11q- and deletion 17p had a markedly worse prognosis, with median OS of 4.9 versus 14.7 years (P < .001). Most treated patients (33 of 52) received fludarabine with or without rituximab (FR). Patients treated with FR had a median OS of 12.8 years (standard error, 1.0), which was not statistically different from those treated with alkylator-containing therapy (P = .35).<bold>Conclusion: </bold>Although median TFS of 11q- patients in this cohort was short at 2.5 years, OS remains long at 14.7 years, even when most patients received initial treatment without alkylators.
- Subjects
BRITISH Columbia; CANADA; CHROMOSOMES; CHRONIC lymphocytic leukemia; GENETICS; LONGITUDINAL method; GENETIC mutation; SURVIVAL analysis (Biometry); FLUORESCENCE in situ hybridization
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2017, Vol 17, Issue 6, p382
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2017.04.001